ASCO 2020: ARAMIS Shows Improved Overall Survival With Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Improvements were also seen in time to onset of cancer-related symptoms and need for subsequent chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.